Literature DB >> 15364837

Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery.

Wei Pan1, Tatjana Pintar, James Anton, Vei-Vei Lee, William K Vaughn, Charles D Collard.   

Abstract

BACKGROUND: Statin therapy in nonsurgical patient populations is associated with a significant reduction in adverse cardiovascular events, including death, myocardial infarction (MI), and stroke. Recently, statin therapy was shown to be associated with a reduced incidence of postoperative mortality in patients undergoing major noncardiac vascular surgery. We investigated the influence of preoperative statin therapy on adverse outcomes after primary coronary artery bypass graft (CABG) surgery. METHODS AND
RESULTS: A retrospective cohort study of patients undergoing primary CABG surgery with cardiopulmonary bypass (CPB) (n=1663) between January 1, 2000 and December 31, 2001 at the Texas Heart Institute was performed. Patients were classified into 2 groups: patients receiving preoperative statin therapy (n=943) and patients not receiving preoperative antihyperlipidemic therapy (n=720). To determine if preoperative statin therapy was independently associated with a reduction in the risk of adverse postoperative outcomes, multivariate stepwise logistic regression was performed controlling for patient demographics, medical history, and preoperative medications. Multivariate logistic regression analysis demonstrated that preoperative statin therapy was independently associated with a significant reduction ( approximately 50%) in the risk of 30-day all-cause mortality (3.75% versus 1.80%; P<0.05). The adjusted odds ratio for early mortality in patients receiving preoperative statin therapy compared with patients not receiving antihyperlipidemic agents was 0.53 (95% CI, 0.28 to 0.99). Statin therapy was not independently associated with a reduced risk of postoperative MI, cardiac arrhythmias, stroke, or renal dysfunction. In an attempt to further control for selection bias related to the choice of therapy, multivariate analysis of a propensity-matched cohort of 1362 patients revealed that preoperative statin therapy was independently associated with a significant reduction in the composite endpoint of 30-day all-cause mortality and stroke (7.1% versus 4.6%; P<0.05).
CONCLUSIONS: Preoperative statin therapy may reduce the risk of early mortality after primary CABG surgery with CPB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364837     DOI: 10.1161/01.CIR.0000138316.24048.08

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

1.  Declining in-hospital mortality in patients undergoing coronary bypass surgery in the United States irrespective of presence of type 2 diabetes or congestive heart failure.

Authors:  Mohammad Reza Movahed; Radhakrishnan Ramaraj; Ali Khoynezhad; Mehrnoosh Hashemzadeh; Mehrtash Hashemzadeh
Journal:  Clin Cardiol       Date:  2012-05       Impact factor: 2.882

2.  Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting.

Authors:  Tjörvi E Perry; Jochen D Muehlschlegel; Kuang-Yu Liu; Amanda A Fox; Charles D Collard; Simon C Body; Stanton K Shernan
Journal:  Anesthesiology       Date:  2010-03       Impact factor: 7.892

3.  Statin use associates with a lower incidence of acute kidney injury after major elective surgery.

Authors:  Amber O Molnar; Steven G Coca; Phillip J Devereaux; Arsh K Jain; Abhijat Kitchlu; Jin Luo; Chirag R Parikh; J Michael Paterson; Nausheen Siddiqui; Ron Wald; Michael Walsh; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 10.121

Review 4.  Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update.

Authors:  Nanette K Wenger
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  [Preoperative evaluation and perioperative management of patients with increased cardiovascular risk].

Authors:  D Mergner; P Rosenberger; K Unertl; H K Eltzschig
Journal:  Anaesthesist       Date:  2005-05       Impact factor: 1.041

6.  High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.

Authors:  Frederic T Billings; Patricia A Hendricks; Jonathan S Schildcrout; Yaping Shi; Michael R Petracek; John G Byrne; Nancy J Brown
Journal:  JAMA       Date:  2016-03-01       Impact factor: 56.272

7.  Does high-dose perioperative use of statins ameliorate acute kidney injury following cardiac surgery?

Authors:  Roger van Groenendael; Peter Pickkers
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 8.  Cardioprotection during cardiac surgery.

Authors:  Derek J Hausenloy; Edney Boston-Griffiths; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2012-03-22       Impact factor: 10.787

9.  Statin use and neurologic morbidity after coronary artery bypass grafting: A cohort study.

Authors:  M A Koenig; M A Grega; M M Bailey; L D Pham; S L Zeger; W A Baumgartner; G M McKhann
Journal:  Neurology       Date:  2009-11-11       Impact factor: 9.910

Review 10.  Inhibition of mitochondrial membrane permeability as a putative pharmacological target for cardioprotection.

Authors:  D Morin; R Assaly; S Paradis; A Berdeaux
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.